|
Volumn 33, Issue 5, 2001, Pages 2767-2769
|
Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients
a a a a a a a a a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
ACICLOVIR;
COTRIMOXAZOLE;
CYCLOSPORIN;
INTERLEUKIN 2 RECEPTOR ANTIBODY;
MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;
NYSTATIN;
PREDNISOLONE;
ADOLESCENT;
ADULT;
ALLOGRAFT;
CLINICAL ARTICLE;
CLINICAL TRIAL;
COMORBIDITY;
CONFERENCE PAPER;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG EFFICACY;
DRUG SAFETY;
FEMALE;
GRAFT REJECTION;
GRAFT SURVIVAL;
HUMAN;
HYPERLIPIDEMIA;
INFECTION;
KIDNEY TRANSPLANTATION;
MALE;
PRIORITY JOURNAL;
RECIPIENT;
SIDE EFFECT;
ADOLESCENT;
ADULT;
ANTIBODIES, MONOCLONAL;
COMORBIDITY;
DIABETES MELLITUS;
FEMALE;
FOLLOW-UP STUDIES;
GRAFT REJECTION;
HISTOCOMPATIBILITY TESTING;
HUMANS;
HYPERTENSION;
IMMUNOGLOBULIN G;
IMMUNOSUPPRESSION;
IMMUNOSUPPRESSIVE AGENTS;
ISOANTIBODIES;
KIDNEY TRANSPLANTATION;
MIDDLE AGED;
MYOCARDIAL ISCHEMIA;
RECOMBINANT FUSION PROTEINS;
SAFETY;
TIME FACTORS;
TRANSPLANTATION, HOMOLOGOUS;
|
EID: 0034898879
PISSN: 00411345
EISSN: None
Source Type: Journal
DOI: 10.1016/S0041-1345(01)02184-4 Document Type: Conference Paper |
Times cited : (31)
|
References (21)
|